Translated from our German original by AI. The German text was researched, written, and edited by the Psychedelia Foundation team and remains the authoritative version.
The experimental drug DT120 is a pharmaceutically optimised new formulation of LSD D-tartrate from the biopharmaceutical company Definium Therapeutics, available in tablet form. DT120 has produced promising results in a late-stage clinical trial in patients with major depression. Definium Therapeutics announced the findings. According to the company, the drug helped patients reach significantly lower scores on a standard depression scale, which means the trial’s primary objective was met.
The trial enrolled 149 adults aged 18 to 74 who had been diagnosed with major depression. DT120, an ergoline derivative, takes effect through the activation of serotonin receptors in the brain, which temporarily alter perception, mood, and thinking.
The safety profile was also positive. The treatment was generally well tolerated. The majority of side effects were mild to moderate and occurred predominantly on the day of dosing. The researchers observed no serious safety problems and no increase in suicidal thoughts.
Definium Therapeutics sees the data as an important step towards an application for approval to the US Food and Drug Administration (FDA). A second late-stage clinical trial in the treatment of depression is already under way.
Major depression is considered the second most common mental illness in the United States, affecting more than 21 million Americans each year.
